WASHINGTON (October 22) -- Today, the U.S. Department of the Treasury proposed regulations implementing the Comprehensive Outbound Investment National Security (COINS) Act. The proposal would restrict certain U.S. investments in Chinese biotechnology companies, including those involved in drug development, genetic sequencing, and biomanufacturing. The rules would affect several forms of investment, including equity investments, certain financing arrangements, and joint ventur

WASHINGTON (September 30) -- Today, the Centers for Medicare & Medicaid Services moved to finalize the Global Benchmark for Efficient Drug Pricing (GLOBE) model. Incubate's executive director, John Stanford, issued the following statement: "Incubate opposes the GLOBE demonstration model because it moves Medicare further down the path toward government-imposed drug pricing tied to foreign government price controls. "Developing a new medicine takes years of research, billions o

September 13 -- or 9/13 -- is a reminder of a disparity in federal law that continues to shape which new medicines receive investment. Under the Inflation Reduction Act (IRA), small molecule drugs become eligible for Medicare price setting just nine years after FDA approval, compared with 13 years for biologics. That four-year difference, known as the "pill penalty," gives investors an incentive to favor biologics over small molecule medicines. Drug development is a long an